Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0113-6856 first-in-human dose escalation study in healthy volunteers
NCT05521256Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0113-6856 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Adverse Events at 42 days. Started Aug 2022; status: completed.
02
Drugs
NNC0113-6856
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05521256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521256.